Cancer Cell
Volume 37, Issue 4, 13 April 2020, Pages 514-529
Journal home page for Cancer Cell

Review
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition

https://doi.org/10.1016/j.ccell.2020.03.010Get rights and content
Under an Elsevier user license
open archive

Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in patients with advanced hormone-positive breast cancer. The efficacy of this strategy is, however, limited by innate or acquired resistance mechanisms and its application to other tumor types is still uncertain. Here, through an integrative analysis of sensitivity and resistance mechanisms, we discuss the use of CDK4/6 inhibitors in combination with available targeted therapies, immunotherapy, or classical chemotherapy with the aim of improving future therapeutic uses of CDK4/6 inhibition in a variety of cancers.

Keywords

breast cancer
cell-cycle kinases
cyclin-dependent kinases
resistance to cancer therapies

Cited by (0)

2

Present address: Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Avenida de Roma, s/n 33011 Oviedo, Spain